A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Conditions
Breast Cancer · Endometrial Cancer · Ovarian Cancer · Lung Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma · Solid Tumor · Cervical Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
Contact: Study coordinator (Elizabeth Griffith- Gilmore) · elizabeth.griffith@scri.com · 904-380-2418Massachusetts General Hospital, Boston, Massachusetts, United States
Mayo Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Research Recruitment) · mayocliniccancerstudies@mayo.edu · 507-284-2511Washington Univ. School of Medicine, St Louis, Missouri, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Carolina BioOncology Institute, Huntersville, North Carolina, United States
UH Cleveland Medical Center, Cleveland, Ohio, United States
Sarah Cannon Nashville, Nashville, Tennessee, United States
NEXT Oncology, Austin, Texas, United States
Contact: Study coordinator (Recruitment Coordinator) · NXTAUS_Coordinators@nextoncology.com · 737-610-5200MD Anderson Cancer Center, Houston, Texas, United States
START Center for Cancer Research, San Antonio, Texas, United States
START Center for Cancer Research, West Valley City, Utah, United States
NEXT Oncology, Fairfax, Virginia, United States
Contact: Study coordinator (Referral Coordinator) · NXTAUS_Coordinators@nextoncology.com · (703) 783-4518Froedtert & MCW Cancer Center, Milwaukee, Wisconsin, United States
PanOncology Trials, San Juan, Puerto Rico